Neoplasia最新文献

筛选
英文 中文
Treatment-associated remodeling of a mitochondrial translation-related gene set in paired pretreatment and residual triple-negative breast tumors. 预处理和残留三阴性乳腺肿瘤中线粒体翻译相关基因组的治疗相关重塑
IF 4.8 2区 医学
Neoplasia Pub Date : 2026-11-10 DOI: 10.1016/j.neo.2026.101395
Xiaoyuan Weng, Yanqi Tang, Qianqian Li, Xiyin Huang, Jinsheng Wang, Jianqing Lin
{"title":"Treatment-associated remodeling of a mitochondrial translation-related gene set in paired pretreatment and residual triple-negative breast tumors.","authors":"Xiaoyuan Weng, Yanqi Tang, Qianqian Li, Xiyin Huang, Jinsheng Wang, Jianqing Lin","doi":"10.1016/j.neo.2026.101395","DOIUrl":"https://doi.org/10.1016/j.neo.2026.101395","url":null,"abstract":"<p><strong>Background: </strong>Longitudinal transcriptional remodeling can reveal treatment-associated tumor states. We examined how a fixed 117-gene nuclear-encoded mitochondrial-translation-related set (MT117) changes across treatment in triple-negative breast cancer (TNBC) and whether its change is isolated or accompanied by other transcriptional programs.</p><p><strong>Methods: </strong>We analyzed five public longitudinal datasets. The primary analysis used 19 paired pretreatment and residual TNBC tumors from GSE260693. External or auxiliary analyses used six strict TNBC and 27 all-subtype pairs from GSE240671, seven TNBC pairs from GSE43816, malignant-cell pseudobulk from GSE246613, and chemotherapy-persistent PDX/cell-line systems from GSE164715. Patients or model systems were the inferential units.</p><p><strong>Results: </strong>MT117 decreased in GSE260693 (mean paired change, -0.754; 95% CI, -1.051 to -0.456; paired t P = 4.68 × 10^-5), with decreases in 18 of 19 patients, alongside decreases in multiple contextual programs. In GSE240671, the TNBC-minus-non-TNBC difference was 0.099 (95% CI, -0.247 to 0.445; P = 0.575), providing no evidence of TNBC specificity. In the distinct pembrolizumab-plus-radiotherapy GSE246613 cohort, 11 of 13 malignant-cell pairs decreased (mean, -0.131; 95% CI, -0.267 to 0.004; P = 0.0567), but matched-module and covariate-adjusted analyses did not establish pathway-specific independence. Both external paired TNBC cohorts had confidence intervals crossing zero, and only one of four persistent experimental systems followed the primary human direction.</p><p><strong>Conclusions: </strong>MT117 is best interpreted as an annotation-defined treatment-associated transcriptional signal that co-occurs with other transcriptional changes. Mitochondrial protein synthesis was not directly measured. The findings do not establish selective mitochondrial-translation inhibition, TNBC specificity, a universal persistence mechanism, or a validated biomarker.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"83 ","pages":"101395"},"PeriodicalIF":4.8,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epitranscriptomic regulation contributes to multiple myeloma biology and offers potential therapeutic targets. 表观转录组调控有助于多发性骨髓瘤生物学和提供潜在的治疗靶点。
IF 4.8 2区 医学
Neoplasia Pub Date : 2026-11-07 DOI: 10.1016/j.neo.2026.101396
Amr Ali Mohamed Abdelgawwad El-Sehrawy, Saja Khalil Ibrahim, Sarmad S Abdullah, Ahmed Hjazi, Priya Priyadarshini Nayak, Navin Kumar Tailor, Aseel Smerat, Salamn M Abd, Tina Saeed Basunduwah, Chou-Yi Hsu
{"title":"Epitranscriptomic regulation contributes to multiple myeloma biology and offers potential therapeutic targets.","authors":"Amr Ali Mohamed Abdelgawwad El-Sehrawy, Saja Khalil Ibrahim, Sarmad S Abdullah, Ahmed Hjazi, Priya Priyadarshini Nayak, Navin Kumar Tailor, Aseel Smerat, Salamn M Abd, Tina Saeed Basunduwah, Chou-Yi Hsu","doi":"10.1016/j.neo.2026.101396","DOIUrl":"https://doi.org/10.1016/j.neo.2026.101396","url":null,"abstract":"<p><p>RNA modifications are being investigated as contributors to multiple myeloma (MM) biology alongside genomic lesions and bone marrow interactions. This narrative review examines N⁶-methyladenosine (m⁶A), 5-methylcytosine (m⁵C), adenosine-to-inosine editing, and pseudouridylation, with emphasis on the distinction between MM-specific findings and mechanisms proposed from other systems. Functional studies in MM cells and animal models link METTL3, WTAP, FTO, ALKBH5, and YTHDF2 to selected growth, metabolic, and treatment-response programs. Adenosine deaminase acting on RNA 1 (ADAR1) has been implicated in GLI1 editing and regulation of double-stranded RNA sensing during lenalidomide exposure. Patient expression and outcome associations support clinical relevance but do not establish that these regulators determine disease behavior. Evidence for m⁵C is more limited, including an NSUN2-exosomal MALAT1 mechanism in myeloma bone disease, while the pseudouridylation studies discussed here largely concern non-myeloma cancers. Stage-specific regulatory changes across precursor disease and relapse remain hypotheses requiring longitudinal testing. Therapeutic approaches include enzyme inhibition, targeted protein degradation, and RNA-directed strategies; most remain preclinical, and several have been evaluated mainly outside MM. Plasma cell-free RNA studies provide early diagnostic observations, but modification-aware liquid biopsy has not been clinically validated for MM risk stratification, treatment selection, or relapse prediction. Progress will depend on disease-specific target validation, selective delivery, assessment of normal hematopoietic effects, and prospective clinical studies. Epitranscriptomic regulation therefore offers a useful research framework for understanding and potentially targeting MM, without displacing the established contribution of genomic and clinical risk factors.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"83 ","pages":"101396"},"PeriodicalIF":4.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA signatures associated with exhausted CD8⁺T cells for assessing the immune microenvironment and drug sensitivity in pancreatic adenocarcinoma. 与耗尽CD8 + T细胞相关的LncRNA特征用于评估胰腺腺癌的免疫微环境和药物敏感性。
IF 4.8 2区 医学
Neoplasia Pub Date : 2026-11-07 DOI: 10.1016/j.neo.2026.101394
Jiahui Feng, YuTing Mo, Dezhong Yan, Jie Cheng, Lei Peng
{"title":"LncRNA signatures associated with exhausted CD8⁺T cells for assessing the immune microenvironment and drug sensitivity in pancreatic adenocarcinoma.","authors":"Jiahui Feng, YuTing Mo, Dezhong Yan, Jie Cheng, Lei Peng","doi":"10.1016/j.neo.2026.101394","DOIUrl":"https://doi.org/10.1016/j.neo.2026.101394","url":null,"abstract":"<p><strong>Objectives: </strong>Pancreatic adenocarcinoma (PAAD) is an aggressive malignancy with generally poor prognosis characterized by significant immune evasion driven primarily by its immunosuppressive tumor microenvironment (TME). A central mechanism underlying this evasion is T cell exhaustion (Tex), particularly in CD8⁺T cells, which limits effective anti-tumor immune responses. This study aimed to identify exhausted CD8⁺T cell-related long non-coding RNAs (CD8TexRLs) and evaluate their clinical relevance, with a focus on constructing a prognostic model, assessing immune microenvironment features, and identifying functionally important lncRNA candidates.</p><p><strong>Basic methods: </strong>To elucidate underlying mechanisms and therapeutic implications, comprehensive analyses covering pathway enrichment, TMB, immune landscape profiling, and drug response prediction were conducted. PAAD samples were further stratified into distinct molecular subtypes using ConsensusClusterPlus. Tumor clonogenic assays and subcutaneous tumor modeling were employed to investigate the impact of AC053503.1 overexpression and knockdown in CD8⁺T cell models on PAAD cell proliferation. Immunohistochemistry revealed that AC053503.1 knockdown in CD8⁺T cells significantly enhanced the tumor proliferation rate.</p><p><strong>Main results: </strong>Seven signature CD8TexRLs-AL162424.1, MIR3142HG, LINC02004, AC053503.1, FLRT1, AC068580.2, and AP005233.2-were identified and integrated into a prognostic model that divided patients into high- and low-risk groups. High-risk individuals displayed pronounced enrichment of B-cell receptor signaling and cytosolic DNA-sensing pathways, together with increased TMB and an altered immune landscape. The model also identified differences in immune features and predicted drug sensitivity between risk groups. Stratification into molecular subtypes further demonstrated distinct immune profiles and predicted therapeutic sensitivities. Functional validation revealed that lncRNA AC053503.1 acts as a tumor suppressor in PAAD, with its knockdown promoting tumor proliferation.</p><p><strong>Conclusions: </strong>In summary, our research delineates the complex role of exhausted CD8⁺T cells within the PAAD tumor microenvironment and establishes CD8TexRLs as promising biomarkers for predicting both immunotherapy responses and patient survival. Particularly, functional characterization confirmed lncRNA AC053503.1 as a suppressor of PAAD proliferation, revealing new avenues for targeted therapeutic development.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"83 ","pages":"101394"},"PeriodicalIF":4.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preserving malignant provenance in single-cell cancer atlases: lessons from Ewing sarcoma plasticity. 保存单细胞癌症图谱中的恶性来源:来自尤因肉瘤可塑性的教训。
IF 4.8 2区 医学
Neoplasia Pub Date : 2026-11-06 DOI: 10.1016/j.neo.2026.101392
Ge Zhao, Zhijie Hu, Baicheng Yang, Wei Shi
{"title":"Preserving malignant provenance in single-cell cancer atlases: lessons from Ewing sarcoma plasticity.","authors":"Ge Zhao, Zhijie Hu, Baicheng Yang, Wei Shi","doi":"10.1016/j.neo.2026.101392","DOIUrl":"https://doi.org/10.1016/j.neo.2026.101392","url":null,"abstract":"<p><p>Single-cell atlases increasingly organize tumors according to recurrent transcriptional states, but state-based integration can weaken or obscure the molecular evidence that distinguishes malignant from non-malignant provenance. Ewing sarcoma provides a mechanistically tractable example because FET::ETS fusions anchor malignant provenance while EWSR1::FLI1 regulatory output spans proliferative, migratory, mesenchymal and matrix-producing states, including cancer-associated fibroblast-like malignant populations. We propose malignant-to-stromal annotation leakage as a testable post-identification failure mode in which provenance-defining evidence is weakened or discarded during reference mapping, annotation or atlas reuse, allowing transcriptional similarity to become a surrogate for cellular identity. Such misassignment can distort estimates of stromal abundance, cell-cell communication, prognostic signatures and therapeutic target attribution. We therefore propose a provenance-aware architecture that keeps malignant provenance, oncogenic regulatory activity, phenotypic state and spatial or clinical context separately traceable while retaining uncertainty. We further outline an evidence hierarchy and a falsifiable benchmarking strategy based on orthogonal molecular evidence, supported where possible by spatial and pathological validation. Although Ewing sarcoma provides the principal exemplar, the framework is designed for testing in other tumors in which plastic malignant states converge transcriptionally with non-malignant compartments.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"83 ","pages":"101392"},"PeriodicalIF":4.8,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
S100A11 promotes immunosuppressive tumour-associated macrophage polarisation with SIRT6-associated changes in SMAD3 acetylation and SMAD2/3 activation in colorectal cancer. 在结直肠癌中,S100A11通过sirt6相关的SMAD3乙酰化和SMAD2/3激活变化,促进免疫抑制肿瘤相关巨噬细胞极化。
IF 4.8 2区 医学
Neoplasia Pub Date : 2026-11-05 DOI: 10.1016/j.neo.2026.101389
Yong Huang, Xiuhua Shi, Weichao Hu, Xidong Lin, Zhaoying Wu, Hao Xie, Lishuai Xu, Jie Wang, Li Xu, Junwei Zou
{"title":"S100A11 promotes immunosuppressive tumour-associated macrophage polarisation with SIRT6-associated changes in SMAD3 acetylation and SMAD2/3 activation in colorectal cancer.","authors":"Yong Huang, Xiuhua Shi, Weichao Hu, Xidong Lin, Zhaoying Wu, Hao Xie, Lishuai Xu, Jie Wang, Li Xu, Junwei Zou","doi":"10.1016/j.neo.2026.101389","DOIUrl":"https://doi.org/10.1016/j.neo.2026.101389","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) develops not only through malignant epithelial cells but also through immune-cell reprogramming within the tumour microenvironment. Tumour-associated macrophages (TAMs) play a central role in mediating immune suppression, but how tumour-associated cues drive their immunosuppressive programming remains poorly defined.</p><p><strong>Methods: </strong>Public CRC single-cell transcriptomic analysis, 20 paired CRC and adjacent non-tumour tissues, THP-1-derived macrophage polarisation models, and HCT116-conditioned TAM-like macrophages were analysed. Selected findings were validated in primary human monocyte-derived macrophages and SW480 CRC cells. S100A11 gain- and loss-of-function assays, SIRT6 rescue experiments, coimmunoprecipitation, immunofluorescence, Western blotting, quantitative PCR, flow cytometry, SMAD3 immunoprecipitation, TGF-β neutralisation, and CRC-cell functional assays were performed to investigate the underlying mechanism and functional consequences. An immunodeficient HCT116 xenograft tumour-growth model and an in vitro HCT116/CD8+ T-cell co-culture system were further used to assess tumour growth and CD8+ T-cell activation and effector-marker expression, respectively.</p><p><strong>Results: </strong>S100A11 was recurrently detected in monocyte/macrophage compartments across CRC single-cell datasets and was elevated in CRC tissues. High S100A11 expression was associated with CD206+ macrophage-related features. S100A11 enhanced an immunosuppressive macrophage phenotype with increased expression of CD206, PPARG/PPARγ, IL-10, TGF-β, PD-L1 and PD-L2 in macrophage models. Mechanistically, S100A11 associated with SIRT6 and was accompanied by reduced SIRT6-SMAD2/3 association, increased SMAD3 acetylation, and increased SMAD2/3 phosphorylation. SIRT6 overexpression partially reversed S100A11- and TGF-β-induced macrophage polarisation. Conditioned medium from S100A11-overexpressing TAM-like macrophages increased HCT116 proliferation, clonogenicity, migration, and invasion, reduced apoptosis, promoted HCT116 xenograft growth, and suppressed CD8+ T-cell activation and effector-marker expression in vitro. These effects were attenuated by SIRT6 overexpression in TAM-like macrophages. TGF-β neutralisation attenuated the conditioned-medium-induced increase in HCT116 proliferation and partially restored CD8+ T-cell CD69 expression.</p><p><strong>Conclusions: </strong>S100A11 is a macrophage-associated regulator of immunosuppressive TAM polarisation in CRC and may contribute to tumour-promoting macrophage reprogramming within the tumour microenvironment. These findings suggest that the S100A11-SIRT6-SMAD3 pathway warrants further investigation as a potential target for macrophage reprogramming in the colorectal cancer immune microenvironment.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"83 ","pages":"101389"},"PeriodicalIF":4.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Co-mutation of KRAS and ARID1A correlates with the MSI/LINE-1 hypermethylation profile in endometrial carcinoma. KRAS和ARID1A的共突变与子宫内膜癌中MSI/LINE-1高甲基化谱相关。
IF 4.8 2区 医学
Neoplasia Pub Date : 2026-11-05 DOI: 10.1016/j.neo.2026.101391
Muhammad Adnan, Laura Libera, Antonio Travaglino, Nora Sahnane, Sofia Facchi, Giorgia Ortelli, Anna Giudici, Tommaso Meschini, Simona De Toffol, Denis Cominetti, Jvan Casarin, Stefano La Rosa, Daniela Furlan
{"title":"Co-mutation of KRAS and ARID1A correlates with the MSI/LINE-1 hypermethylation profile in endometrial carcinoma.","authors":"Muhammad Adnan, Laura Libera, Antonio Travaglino, Nora Sahnane, Sofia Facchi, Giorgia Ortelli, Anna Giudici, Tommaso Meschini, Simona De Toffol, Denis Cominetti, Jvan Casarin, Stefano La Rosa, Daniela Furlan","doi":"10.1016/j.neo.2026.101391","DOIUrl":"https://doi.org/10.1016/j.neo.2026.101391","url":null,"abstract":"<p><strong>Objective: </strong>The interaction between oncogenic signalling and epigenetics in endometrioid endometrial carcinoma (EEC) is poorly defined. We investigated the potential association of KRAS-ARID1A co-mutation axis with a distinct hypermethylator phenotype, affecting focal MLH1 promoter methylation and global DNA methylation (LINE-1).</p><p><strong>Methods: </strong>We analysed an institutional cohort of 83 EECs and a public dataset of 1300 cases (cBioPortal). Molecular profiling included Next-Generation Sequencing (NGS) for KRAS and ARID1A mutations, MS-MLPA for MLH1 promoter methylation, and pyrosequencing for global LINE-1 methylation levels.</p><p><strong>Results: </strong>In large-scale dataset, KRAS mutations significantly associated with MSI (p = 0.003) and MLH1 hypermethylation (p = 0.0001). In our cohort, KRAS-mutated tumours exhibited significantly higher LINE-1 methylation than wild-type cases (p = 0.0079). ARID1A mutations co-occurred in 76% of KRAS-mutated cases in our cohort, consistent with significant co-occurrence observed in cBioPortal dataset (p = 0.001). This dual-mutant KRAS-ARID1A subset defined a distinctive epigenetic signature characterised by the highest global DNA methylation levels (p = 0.0474) and an increased incidence of sporadic mismatch repair deficiency. Multivariable logistic regression demonstrated that this co-mutation pattern remained significant independently of established molecular subtypes of EC. Exploratory survival analyses suggested improved OS in ARID1A-mutated tumours (p = 0.0188) whereas KRAS-mutated tumours showed a trend towards longer DFS (p = 0.0594).</p><p><strong>Conclusions: </strong>The KRAS-ARID1A co-mutation identifies a distinct molecular subset of EEC mainly characterised by sporadic mismatch repair deficiency and global hypermethylation. Moreover, these findings suggest that integrating KRAS/ARID1A status and LINE-1 methylation assessment represents a promising hypothesis that warrants further validation as a tool to subclassify the heterogeneous No Specific Molecular Profile (NSMP) group in independent cohorts.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"83 ","pages":"101391"},"PeriodicalIF":4.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
αvβ3 integrin recycling is associated with the intracellular trafficking and efflux of cRGDfK-modified PLGA nanoparticles. αvβ3整合素循环与crgdfk修饰的PLGA纳米颗粒的细胞内运输和外排有关。
IF 4.8 2区 医学
Neoplasia Pub Date : 2026-11-04 DOI: 10.1016/j.neo.2026.101390
Jingyi Zhu, Siyu Chen, Lingbo Yu, Rui Xu, Huixin Sun, Xiaoya Wang, Xiyan Yao, Qinghua Yu, Defang Ouyang, Yanan Cui
{"title":"αvβ3 integrin recycling is associated with the intracellular trafficking and efflux of cRGDfK-modified PLGA nanoparticles.","authors":"Jingyi Zhu, Siyu Chen, Lingbo Yu, Rui Xu, Huixin Sun, Xiaoya Wang, Xiyan Yao, Qinghua Yu, Defang Ouyang, Yanan Cui","doi":"10.1016/j.neo.2026.101390","DOIUrl":"https://doi.org/10.1016/j.neo.2026.101390","url":null,"abstract":"<p><p>Understanding the cellular transport mechanisms of active-targeting nanocarriers is essential for improving their therapeutic performance. In this study, cRGDfK-modified poly(lactic-co-glycolic acid) nanoparticles (cRGDfK-PLGA-NPs) were developed as an αvβ3 integrin-targeted delivery system, and their cellular uptake, intracellular trafficking, and efflux behaviors were systematically investigated in HeLa cells. Confocal laser scanning microscopy and HPLC analyses demonstrated enhanced cellular uptake of cRGDfK-PLGA-NPs compared with non-modified nanoparticles in HeLa cells. The uptake advantage was associated with αvβ3 integrin targeting, while pathway-inhibition studies suggested contributions from clathrin-mediated endocytosis and macropinocytosis. Following internalization, cRGDfK-PLGA-NPs were rapidly transported to early endosomes (EE), followed by redistribution to the endocytic recycling compartment (ERC) and gradual accumulation in late endosomes (LE). Real-time and fixed-cell colocalization analyses suggested three intracellular trafficking routes: the EE-LE pathway, a proposed EE-ERC-slow efflux pathway, and an EE-fast efflux pathway. Efflux studies indicated a two-stage kinetic process, with an initial rapid efflux phase (∼5 min) and a subsequent slower phase (∼10 min). To further elucidate the underlying mechanism, the intracellular trafficking behavior of the αvβ3 integrin receptor was investigated using an ELISA-based method, revealing a cyclical pattern of endocytosis and recycling with a periodicity of approximately 5 min. Comparative analysis using a cRGDfK fluorescent probe demonstrated that its rapid efflux behavior closely paralleled receptor recycling dynamics, suggesting that the fast efflux pathway of cRGDfK-PLGA-NPs is associated with αvβ3 integrin-mediated recycling, whereas the slower efflux pathway may involve ERC-mediated transport. Overall, this study provides insights into the potential relationship between target-receptor trafficking dynamics and the intracellular fate of active-targeting nanoparticles. These findings offer a theoretical basis for the rational design and optimization of active-targeting nanocarriers and contribute to improving their therapeutic efficacy.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"83 ","pages":"101390"},"PeriodicalIF":4.8,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal profiling of oral squamous cell carcinoma identifies genomic alterations and expression programs associated with betel quid chewing. 口腔鳞状细胞癌的多模态分析确定了与槟榔液咀嚼相关的基因组改变和表达程序。
IF 7.7 2区 医学
Neoplasia Pub Date : 2025-10-01 Epub Date: 2025-08-09 DOI: 10.1016/j.neo.2025.101218
Shih-Chi Su, Chiao-Wen Lin, Mu-Kuan Chen, Yi-Chan Lee, Chun-Wen Su, Shi Bai, Hansraj Jangir, Chun-Yi Chuang, Wen-Hung Chung, Lun-Ching Chang, Shun-Fa Yang
{"title":"Multimodal profiling of oral squamous cell carcinoma identifies genomic alterations and expression programs associated with betel quid chewing.","authors":"Shih-Chi Su, Chiao-Wen Lin, Mu-Kuan Chen, Yi-Chan Lee, Chun-Wen Su, Shi Bai, Hansraj Jangir, Chun-Yi Chuang, Wen-Hung Chung, Lun-Ching Chang, Shun-Fa Yang","doi":"10.1016/j.neo.2025.101218","DOIUrl":"10.1016/j.neo.2025.101218","url":null,"abstract":"<p><p>Betel quid (BQ) chewing is a profound risk for oral squamous cell carcinoma (OSCC) in Southeast Asia. Yet, the detailed mechanisms by which BQ chewing damages the genome and creates a unique tumor niche that ultimately cause OSCC are still not fully understood. To address this, we conducted a multi-omics survey, including exome sequencing of tumor-normal pairs from 261 male patients with OSCC (129 habitual BQ chewers and 132 non-BQ users), alone with integrated single-cell and spatial transcriptomics of a set of tumors. Comparative analyses of the mutational catalog identified enrichment of significantly altered genes (e.g. mutations of TP53 and CHUK, copy gains of MAP3K13 and FADD, copy losses of CDKN2A) associated with BQ chewing. Assessment of oncogenic and co-occurring actionable alterations demonstrated frequently altered oncogenic pathways (Hippo and p53 signaling) and potential combination therapy opportunities linked to BQ use. In addition, evaluation of epithelial, immune, stromal expression programs in the corresponding tissue compartments revealed a shift of tumor microenvironment in BQ-related OSCC, characterized by induced hypoxia of tumor epithelium, altered immunosuppression of dendritic cells, and raised sprouting angiogenesis of tumor endothelium. Quantitative predictions of intercellular communications inferred a more heterogeneous cell-cell crosstalk among BQ-related OSCC, highlighted by extensive interactions of fibroblasts and dendritic cells with other non-epithelial cell types via mostly extracellular matrix-receptor signaling pathways. Collectively, these differences in genomic landscape and tumor niche suggest that OSCC caused by BQ chewing could be an etiological subtype different from their BQ-negative counterparts.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"68 ","pages":"101218"},"PeriodicalIF":7.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-dose DFMO alters protein translation in neuroblastoma. 大剂量DFMO改变神经母细胞瘤中的蛋白质翻译。
IF 4.8 2区 医学
Neoplasia Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1016/j.neo.2025.101215
Andrea T Franson, Kangning Liu, Rohan Vemu, Elizabeth Scadden, Yimei Li, Annette Vu, Michael D Hogarty
{"title":"High-dose DFMO alters protein translation in neuroblastoma.","authors":"Andrea T Franson, Kangning Liu, Rohan Vemu, Elizabeth Scadden, Yimei Li, Annette Vu, Michael D Hogarty","doi":"10.1016/j.neo.2025.101215","DOIUrl":"10.1016/j.neo.2025.101215","url":null,"abstract":"<p><p>DFMO has been studied as a cancer therapeutic at doses ranging from 500 to 9,000 mg/m2/day. Lower doses are favored for cancer prevention studies while higher doses, often with chemotherapy, are studied in refractory cancers. DFMO inhibits the rate-limiting enzyme in polyamine synthesis, ornithine decarboxylase (ODC), an oncogene transcriptionally regulated by MYC. MYC genes are the principal oncogenic drivers of neuroblastoma, and ODC1 is co-amplified in a subset with dismal outcome, so DFMO is a rational therapeutic candidate. Low-dose DFMO has now been FDA-approved for high-risk patients though the mechanisms for its anti-tumor activity, and the exposures required to elicit them, remain obscure. We sought to define biomarkers of activity across exposures achieved in the clinic with low through high-dose DFMO. Polyamines support protein translation by providing spermidine, which is essential to hypusinate (and activate) the elongation factor, eIF5A. Selective binding of polyamines with tRNA and rRNA provide eIF5A-independent mechanisms of translation support. We show that low-dose DFMO does not extend survival in mouse models in vivo nor alter translation biomarkers in vitro. High-dose DFMO consistently extends survival in neuroblastoma models, and, in a subset of neuroblastoma cell lines, inhibits eIF5A hypusination and global translation at achievable concentrations. However, the concentration required to engage these changes across many cell lines exceeded that achievable even with high-dose DFMO. No correlation was seen among MYCN and/or ODC1 copy number and sensitivity to DFMO. Combining high-dose DFMO with additional agents to further deplete tumor polyamines may be necessary to fully engage polyamine-depletion effects on tumors, and more granular measures of translation, including codon-resolution ribosome profiling, may be required to define these effects.</p>","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"68 ","pages":"101215"},"PeriodicalIF":4.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144800599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway. DCZ0014,一种通过B细胞受体信号通路治疗弥漫性大B细胞淋巴瘤的新化合物。
IF 4.8 2区 医学
Neoplasia Pub Date : 2020-08-01 DOI: 10.21203/rs.3.rs-48447/v1
Shuaikang Chang, Bo Li, Yongsheng Xie, Yingcong Wang, Zhijian Xu, Shuhan Jin, D. Yu, Huaping Wang, Yumeng Lu, Yong Zhang, Ruye Ma, Cheng Huang, Weiming Lai, Xiaosong Wu, Weiliang Zhu, Jumei Shi
{"title":"DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.","authors":"Shuaikang Chang, Bo Li, Yongsheng Xie, Yingcong Wang, Zhijian Xu, Shuhan Jin, D. Yu, Huaping Wang, Yumeng Lu, Yong Zhang, Ruye Ma, Cheng Huang, Weiming Lai, Xiaosong Wu, Weiliang Zhu, Jumei Shi","doi":"10.21203/rs.3.rs-48447/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-48447/v1","url":null,"abstract":"Diffuse large B cell lymphoma (DLBCL) is a clinical and genetically heterogeneous lymphoid malignancy. Although R-CHOP (rituximab plus cyclophosphamide, vincristine, doxorubicin, and prednisone) treatment can improve the survival rate of patients with DLBCL, more than 30% of patients exhibit treatment failure, relapse, or refractory disease. Therefore, novel drugs or targeted therapies are needed to improve the survival of patients with DLBCL. The compound DCZ0014 is a novel chemical similar to berberine. In this study, we found that DCZ0014 significantly inhibited the proliferation and activity of DLBCL cells, and induced cell apoptosis. Following treatment with DCZ0014, DLBCL cells accumulated in G0/G1-phase of the cell cycle and showed decreased mitochondrial membrane potential. Additionally, DCZ0014 inhibited DNA synthesis, enhanced DNA damage in DLBCL cells, as well as inhibited Lyn/Syk in B cell receptor signaling pathway. Further experiments demonstrated that DCZ0014 did not significantly affect peripheral blood mononuclear cells. Tumor xenograft model showed that DCZ0014 not only inhibited tumor growth but also extended the survival time of mice. Thus, DCZ0014 showed potential for clinical application in the treatment of patients with DLBCL.","PeriodicalId":48716,"journal":{"name":"Neoplasia","volume":"212 7","pages":"50-61"},"PeriodicalIF":4.8,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72436607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书